Study of rivastigmine for delirium in intensive care is stopped after deathsBMJ 2010; 340 doi: https://doi.org/10.1136/bmj.c2895 (Published 28 May 2010) Cite this as: BMJ 2010;340:c2895
- Tony Sheldon
- 1Utrecht, Netherlands
Doubts have been raised about the use of rivastigmine to treat delirium in intensive care patients after a national trial in the Netherlands was halted because of safety concerns.
The double blind trial intended to study 440 patients in six hospitals, but was wound up prematurely after its data safety monitoring board found higher mortality among patients receiving rivastigmine than those taking placebo. A total of 104 patients completed the trial, with 12 deaths among the 54 patients taking the drug compared with four deaths among the 50 patients receiving placebo.
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial